Navigation Links
Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock

ALPHARETTA, Ga., Oct. 16 /PRNewswire/ -- Cellu Tissue Holdings, Inc. ("Cellu Tissue") today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of shares of its common stock. The offered shares will include shares to be sold by Cellu Tissue and shares to be sold by stockholders of the company. The total number of shares to be offered, the allocation of shares to be sold as between Cellu Tissue and stockholders and the price range for the offering have not yet been determined. Cellu Tissue intends to use the net proceeds it receives from the offering to pay down certain indebtedness, including, but not limited to, potentially redeeming or repurchasing a portion of its outstanding senior secured notes, and the remaining net proceeds, if any, for general corporate purposes. Cellu Tissue will not receive any of the proceeds from the sale of shares by the selling stockholders.

Cellu Tissue intends to apply to list the common stock on the New York Stock Exchange under the ticker symbol "CLU."

Goldman, Sachs & Co. and J.P. Morgan Securities Inc. will act as joint book running managers for the offering. The offering will only be made by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained by contacting either Goldman, Sachs & Co., at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, by telephone at 1-866-471-2526 or by emailing, or J.P. Morgan Securities Inc. at National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, New York, NY, 11245, or by telephone at 718-242-8002.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale of securities would be unlawful prior to their registration and qualification under the securities laws of any such state or jurisdiction.

SOURCE Cellu Tissue Holdings, Inc.

SOURCE Cellu Tissue Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
3. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
6. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
7. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
8. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
9. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
10. Cellular construction methods emulated
11. GreenField Ethanol and Enerkem Announce Plans to Make Cellulosic Ethanol a Commercial Reality
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):